Keytruda: NICE Rejects English Funding For Endometrial Cancer But Says Yes For Renal Cancer
BMS's Onureg Also Wins Thumbs Up From NICE
Executive Summary
NICE has preliminarily rejected MSD’s drug for endometrial cancer in a decision that contrasts with that of its health technology assessment counterpart in Scotland.
You may also be interested in...
Scottish HTA Nod For Keytruda In Endometrial Carcinoma Marks UK First
Scotland has approved reimbursement for MSD’s Keytruda in combination with Eisai’s Lenvima for endometrial carcinoma. Meanwhile, a recommendation in England has been delayed.
England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.